Sector News

Merck KGaA to buy Sigma-Aldrich for $17 billion

September 22, 2014
Life sciences
(Reuters) – German drugs and chemicals maker Merck KGaA (MRCG.DE) said on Monday it agreed to acquire Sigma-Aldrich (SIAL.O) for $17 billion (10.41 billion pounds) in cash to boost its life science business.
 
The deal, approved by Sigma-Aldrich’s management, will see Merck acquire all shares for $140 apiece in cash.
 
That represents a 37 percent premium over the latest closing price of $102.37 on Sept. 19 and a 36 percent premium to the one-month average closing price, according to Merck.
 
(Reporting by Ludwig Burger; Editing by Georgina Prodhan)

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend